Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses - confirmed in a representative tumor biopsy - all within two weeks of initial treatment Halifax, Nova Scotia--(Newsfile Corp. - October 20, 2025) - Sona Nanotech Inc. , (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona "), is pleased to announce the completion of its first-in-human... Read More

Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona "), announces that it will host a webinar on Monday, October 20 th at noon EDT to discuss its first-in-human, early feasibility clinical study for its Targeted Hyperthermia Therapy cancer treatment. Ten advanced stage melanoma patients who were failing to respond to standard immunotherapy... Read More

Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona "), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, is pleased to provide an update on the first-in-human early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage... Read More

Halifax, Nova Scotia--(Newsfile Corp. - July 23, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona "), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, has received Nova Scotia Health Research Ethics Board ("REB") approval to conduct its proposed pilot human clinical trial study (the "Pilot Study") of its... Read More

Trial is expected to provide key insights on safety, tolerability and immune system response for its THT treatment of late-stage melanoma patients Halifax, Nova Scotia--(Newsfile Corp. - July 7, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that a... Read More

Halifax, Nova Scotia--(Newsfile Corp. - June 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona "), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that it has received ethics committee approval to proceed with its previously announced early feasibility study of its Targeted Hyperthermia Therapy... Read More

First Patients Expected to be Enrolled This Month Halifax, Nova Scotia--(Newsfile Corp. - June 16, 2025) - Sona Nanotech Inc . (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, today announced that it has entered into a clinical trial agreement for an early feasibility study clinical... Read More

Halifax, Nova Scotia--(Newsfile Corp. - May 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") is pleased to announce positive results from a required preclinical safety study evaluating for toxicity issues when animals are injected with its proprietary gold nanorods, conducted by CBSET, Inc. Donald Hodges, PhD, DSP, DABT, Head of Integrated Toxicology at CBSET, Inc., commented, "This study... Read More

Halifax, Nova Scotia--(Newsfile Corp. - May 15, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") is pleased to announce the successful completion of bacterial endotoxin testing ("BET") on Sona's uniquely biocompatible gold nanorods using the Limulus Amebocyte Lysate ("LAL") method at a leading global provider of laboratory testing and expert advisory services for MedTech and pharmaceutical... Read More

Vancouver, British Columbia, and Halifax, Nova Scotia--(Newsfile Corp. - May 7, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) (" BioVaxys ") and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (" Sona ") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in... Read More

Halifax, Nova Scotia--(Newsfile Corp. - May 1, 2025) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has granted 2,135,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") of which 1,855,0000 have been granted to Directors and Officers. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every... Read More

Halifax, Nova Scotia--(Newsfile Corp. - March 19, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") is pleased to provide updated data confirming efficacy of its Targeted Hyperthermia Therapy ("THT") cancer treatment in an immunotherapy resistant cancer. In this follow-up data to the previously... Read More

Halifax, Nova Scotia--(Newsfile Corp. - February 12, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") is pleased to announce that its recently published findings from its " Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically 'Cold' Tumors " study will be presented at the international 19th Canadian... Read More

Halifax, Nova Scotia--(Newsfile Corp. - January 13, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") is pleased to announce that the now complete findings from our previously announced pre-clinical breast cancer and melanoma efficacy studies have been published in the peer-reviewed scientific journal, Frontiers in Immunology . This research article includes new follow-up data which provides a... Read More

Halifax, Nova Scotia--(Newsfile Corp. - December 11, 2024) - Sona Nanotech Inc. ( CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain... Read More

Halifax, Nova Scotia--(Newsfile Corp. - November 7, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") is pleased to announce that its Chief Scientific Officer, Dr. Len Pagliaro, has been invited to showcase Sona's developing Targeted Hyperthermia Therapy ("THT") cancer treatment today at the Nanotechnology Characterization Laboratory ("NCL"). Sona will be one of six commercial and academic... Read More

Halifax, Nova Scotia--(Newsfile Corp. - October 21, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") is pleased to announce the issuance of U.S. Patent No. 12117447 by the U.S. Patent and Trademark Office to the Company, entitled, " Metal Nanoparticles and Methods of Making Same ". This patent covers the Company's proprietary process for manufacturing gold nanorods without the use of the... Read More

Halifax, Nova Scotia--(Newsfile Corp. - October 9, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will... Read More

Halifax, Nova Scotia--(Newsfile Corp. - September 24, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company " or " Sona ") is pleased to announce that it has closed its non-brokered private placement that was announced on September 5, 2024 with the issuance of 6,575,000 common shares (each, a " Share ") at $0.25 per share (the " Financing ") for gross proceeds of $1,643,750. One Insider of Sona subscribed for... Read More

Halifax, Nova Scotia--(Newsfile Corp. - September 5, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company " or " Sona ") is pleased to announce that it has closed its non-brokered private placement that was announced on July 31, 2024 with the issuance of 6,000,000 common shares (each, a " Share ") at $0.25 per share (the " Financing "). As previously disclosed, Sona intends to use the net proceeds of the... Read More

Halifax, Nova Scotia--(Newsfile Corp. - July 31, 2024) - Sona Nanotech Inc. ( CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") is pleased to announce that it plans to raise up to $1,500,000 through a private placement financing (the " Financing ") of up to 6,000,000 common shares of Sona (each, a " Share ") at a price of $0.25 per Share (the " Offering Price "). Insiders and certain other existing shareholders of Sona... Read More

Halifax, Nova Scotia--(Newsfile Corp. - June 26, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the "Study") indicates that, beyond shrinking tumors... Read More

Halifax, Nova Scotia--(Newsfile Corp. - June 20, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted... Read More

Halifax, Nova Scotia--(Newsfile Corp. - May 21, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to advise that it has appointed Dr. Carman Giacomantonio MD, MSc., FRCSC (Cav.) to be the Company's Chief Medical Officer. Dr. Giacomantonio is a practicing Surgical Oncologist at the QEII Health Sciences Centre and a Professor of Surgery at Dalhousie University. Dr. Giacomantonio leads a... Read More

Halifax, Nova Scotia--(Newsfile Corp. - April 29, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces further results from the triple negative breast cancer murine model portion of its current research study at Dalhousie University (the "Study") which confirms that the previously reported tumor volume reduction was due to activation of a tumor specific systemic immune response. These... Read More

Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce further positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). The Company was provided with data... Read More